CJC-1295 and Sermorelin are both synthetic analogs of growth hormone-releasing hormone (GHRH), the hypothalamic hormone that tells the pituitary gland to produce and release GH. But they differ dramatically in half-life, dosing frequency, and the nature of the GH release they produce.
Understanding these differences is essential for researchers and clinicians selecting the appropriate GHRH analog for specific protocols — whether the goal is anti-aging optimization, body composition improvement, or recovery support.
For researchers sourcing these compounds, Amino Club provides COA-verified peptides with documented purity testing. Browse peptides →
Sermorelin: The Pioneer GHRH Analog
Sermorelin (GRF 1-29 NH₂) is a 29-amino acid synthetic peptide corresponding to the first 29 amino acids of the 44-amino acid native GHRH molecule. It was FDA-approved in 1997 under the brand name Geref for diagnosing and treating pediatric growth hormone deficiency.¹
Sermorelin binds to the GHRH receptor on pituitary somatotroph cells, stimulating transcription, synthesis, and pulsatile release of endogenous GH. Its half-life is extremely short — approximately 10-20 minutes — meaning its effects are brief, pulsatile, and highly physiological.
Clinical data from the original registration trials showed that sermorelin: increased growth velocity in GH-deficient children, elevated IGF-1 levels to age-appropriate ranges, and maintained normal pituitary-hypothalamic feedback mechanisms (unlike exogenous GH which suppresses them).¹
In adult clinical practice, sermorelin is commonly prescribed by anti-aging and integrative medicine practitioners at doses of 200-300 mcg subcutaneously before bed, leveraging the natural nocturnal GH surge.
CJC-1295: The Engineered Upgrade
CJC-1295 is a 30-amino acid synthetic GHRH analog that exists in two forms:
CJC-1295 without DAC (Mod GRF 1-29)
Also known as Modified GRF 1-29, this version has four amino acid substitutions that improve metabolic stability compared to sermorelin, extending half-life to approximately 30 minutes. It produces GH pulses similar to sermorelin but with slightly greater amplitude and duration. It is typically dosed 2-3 times daily or before bed.
CJC-1295 with DAC
The Drug Affinity Complex (DAC) modification adds a reactive chemical group that allows CJC-1295 to covalently bond with serum albumin after injection. This dramatically extends the functional half-life to approximately 6-8 days, producing sustained GH and IGF-1 elevation with once-weekly dosing.²
A pivotal clinical study by Teichman et al. demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced sustained IGF-1 elevation lasting 6-14 days, with peak IGF-1 increase of 1.5-3x baseline. Multiple doses raised mean IGF-1 by 2x with no evidence of tachyphylaxis.²
Head-to-Head Comparison
| Feature | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) |
|---|---|---|---|
| Half-Life | 10-20 min | ~30 min | 6-8 days |
| Dosing Frequency | Daily (before bed) | 2-3x daily or nightly | 1-2x weekly |
| GH Pattern | Pulsatile (most physiological) | Pulsatile | Sustained/tonic |
| IGF-1 Elevation | Moderate | Moderate-High | High (sustained) |
| FDA History | Approved (1997) | Investigational | Investigational |
| Clinical Data | Extensive | Moderate | Moderate |
Optimal Stacking
Both sermorelin and CJC-1295 are optimally paired with Ipamorelin — a selective GHRP that triggers GH release via the complementary ghrelin pathway. This GHRH + GHRP combination produces synergistic GH amplification (3-6x greater pulses) through a dual-pathway mechanism.³
Sermorelin + Ipamorelin: Best for physiological pulsatile GH release, anti-aging protocols, and long-term use where natural GH patterns are prioritized.
CJC-1295 (w/DAC) + Ipamorelin: Best for sustained IGF-1 elevation, body composition goals, and protocols where dosing convenience is important.
Research Verdict
For anti-aging and longevity:Sermorelin's shorter half-life and physiological pulsatile release pattern more closely mimic natural GH secretion, which many clinicians prefer for long-term health optimization.
For body composition and performance: CJC-1295 with DAC provides stronger, more sustained GH/IGF-1 elevation with greater convenience and compliance due to weekly dosing.
Both are well-tolerated with comparable side effect profiles (mild water retention, occasional headache, transient fatigue).
Sources
- Walker, R.F. "Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging, 2006; 1(4): 307-308.
- Teichman, S.L., et al. "Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295." JCEM, 2006; 91(3): 799-805.
- Raun, K., et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998; 139(5): 552-561.
